Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?

European urology focus - 1 Jan 2026

González-Ginel Ignacio, Rodriguez-Antolin Alfredo, Olmos David, Castro Elena

Abstract excerpt

We review evidence for the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer (mCRPC). Initial approval of these agents in mCRPC was for patients with alterations in BRCA and other homologous recombination repair (HRR) genes. The European Medicines Agency has broadened approval of PARPi combinations with androgen receptor pathway inhibitors to all patients with mCRPC. Nevertheless, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Patient Selection
Share to Poly(ADP-ribose) Polymerase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostatic Neoplasms, Castration-Resistant

Source

Identifiers

PMID: 41353049
DOI: 10.1016/j.euf.2025.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Prostate Cancer: Broad Use or Patient Selection?PMID 41353049Read ↗

PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical DevelopmentSemantic proximity Read ↗

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate CancersSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

PARP Inhibitors in Prostate Cancer.Semantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

Use of PARP inhibitors in prostate cancer: from specific to broader application.Semantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?Semantic proximity Read ↗

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.Semantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.